Loading...

Tekla Life Sciences Investors

HQL•NYSE
Financial Services
Asset Management
$12.81
$0.03(0.23%)

Tekla Life Sciences Investors (HQL) Stock Overview

Explore Tekla Life Sciences Investors’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

A

Score: 82.0/100

Key Financials

Market Cap370.1M
P/E Ratio4.30
EPS (TTM)$-0.48
ROE0.19%
Fundamental Analysis

AI Price Forecasts

1 Week$12.56
1 Month$13.46
3 Months$13.56
1 Year Target$15.15

HQL Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Tekla Life Sciences Investors (HQL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $15.15.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 4.30 and a market capitalization of 370.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
268.50%
↑ 268.50%
Profit Growth
$2.96
↑ 281.60%
EPS Growth
$2.96
↑ 284.81%
Operating Margin
-48.25%
↑ 1726.54%
ROE
18.94%
↑ 281.60%
Dividend Yield
0.00%
↑ 29.69%
Analyst Recommendations data is not available for HQLAnalyst Recommendations details for HQL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

CEO

Daniel R. Omstead M.S,

Headquarters

100 Federal Street, Philadelphia, MA

Founded

1992

Frequently Asked Questions

;